Fortive
Fortive Corporation
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$4.2B
Operating marginCalculated
17.3%
Net assets to total assetsCalculated
55.0%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
17.3%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-5.7%
Capital efficiency
★★☆☆☆position among all companies
9.0%
Revenue and profit
Performance, financial position and capital allocation
Fortive
Recent performance trends
Fortive
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$5.3 billion | US$5.8 billion | US$3.9 billion | US$4.1 billion | US$4.2 billion |
| Operating income | US$0.8 billion | US$1.0 billion | US$0.6 billion | US$0.7 billion | US$0.7 billion |
| Net income | Could not be retrieved | US$0.8 billion | US$0.9 billion | US$0.8 billion | US$0.6 billion |
| Total assets | US$16.5 billion | US$15.9 billion | US$16.9 billion | US$17.0 billion | US$11.7 billion |
| Shareholders' equity | US$9.5 billion | US$9.7 billion | US$10.3 billion | US$10.2 billion | US$6.5 billion |
| Net cash provided by (used in) operating activities | US$1.0 billion | US$1.3 billion | US$1.4 billion | US$1.5 billion | US$1.1 billion |
| Net cash provided by (used in) investing activities | US$-2.6 billion | US$-0.1 billion | US$-0.2 billion | US$-1.8 billion | US$-0.1 billion |
| Net cash provided by (used in) financing activities | US$0.7 billion | US$-1.3 billion | US$32.30 million | US$-0.8 billion | US$-1.4 billion |
| Cash and cash equivalents | US$0.8 billion | US$0.7 billion | US$1.9 billion | US$0.8 billion | US$0.4 billion |
Revenue scale in the same industry
Fortive
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 25 companies
- 29 DexcomFY Dec 2025 US$4.7B
- 30 IlluminaFY Dec 2025 US$4.3B
- 31 FortiveThis companyFY Dec 2025 US$4.2B
- 32 HologicFY Sep 2025 US$4.1B
- 33 The Cooper CompaniesFY Oct 2025 US$4.1B
- … 10 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.1 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-1.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.1 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.4 billion | Consolidated | Disclosed |
| Dividends paid | US$92.20 million | Consolidated | Disclosed |
| Number of employees | 18,000 | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$6.5 billion | Consolidated | Disclosed |
| Non-controlling interests | US$7.70 million | Consolidated | Disclosed |
| Net assets | US$6.5 billion | Consolidated | Disclosed |
| Net sales | US$4.2 billion | Consolidated | Disclosed |
| Operating income | US$0.7 billion | Consolidated | Disclosed |
| Net income | US$0.6 billion | Consolidated | Disclosed |
| Total assets | US$11.7 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$1.6 billion | Consolidated | Disclosed |
| Operating margin | 17.3% | Consolidated | Calculated |
| Net assets to total assets | 55.0% | Consolidated | Calculated |
| Net margin | 13.9% | Consolidated | Calculated |
| Return on equity | 9.0% | Consolidated | Calculated |